<SEC-DOCUMENT>0000950170-25-111283.txt : 20250825
<SEC-HEADER>0000950170-25-111283.hdr.sgml : 20250825
<ACCEPTANCE-DATETIME>20250825194729
ACCESSION NUMBER:		0000950170-25-111283
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250825
DATE AS OF CHANGE:		20250825

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-80035
		FILM NUMBER:		251252340

	BUSINESS ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Deep Track Capital, LP
		CENTRAL INDEX KEY:			0001856083
		ORGANIZATION NAME:           	
		EIN:				853360885
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		200 GREENWICH AVENUE
		STREET 2:		3RD FLOOR
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		2034090812

	MAIL ADDRESS:	
		STREET 1:		200 GREENWICH AVENUE
		STREET 2:		3RD FLOOR
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001856083</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.001 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>08/22/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001029142</issuerCik>
        <issuerName>Dynavax Technologies Corporation</issuerName>
        <issuerCusip>268158201</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">2100 Powell Street</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 720</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Emeryville</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">94608</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Deep Track Biotechnology Master Fund, Ltd.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>15726349</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>15726349</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>15726349</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>13.41</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Deep Track Capital, LP</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>15726349</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>15726349</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>15726349</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>13.41</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>David Kroin</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>15726349</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>15726349</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>15726349</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>13.41</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>
Explanatory Note: Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP, and David Kroin (together, the "Reporting Persons") initially reported their beneficial ownership of the Common Stock, $0.001 par value, of Dynavax Technologies Corporation (the "Issuer") on a Schedule 13G, filed on May 19, 2023, as amended on February 14, 2024. The Reporting Persons subsequently reported their beneficial ownership on a Schedule 13D filed on September 16, 2024, as amended on October 24, 2024 and February 19, 2025 (collectively, the "Schedule 13D"). Pursuant to Rule 13d-1(h), the Reporting Persons are eligible to again report their beneficial ownership on a Schedule 13G and are filing this Amendment No. 2 to Schedule 13G to amend and replace the Schedule 13D.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Dynavax Technologies Corporation</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>2100 Powell Street, Suite 720, Emeryville, CA 94608</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>(i) Deep Track Biotechnology Master Fund, Ltd.
(ii) Deep Track Capital, LP
(iii) David Kroin</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>(i) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands
(ii) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830</principalBusinessOfficeOrResidenceAddress>
        <citizenship>(i) Cayman Islands
(ii) Delaware
(iii) United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <numberOfSharesPersonHas>
          <sharedPowerOrDirectToDispose>Information with respect to the Reporting Persons' ownership of the Common Stock as of August 22, 2025 is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

The amount beneficially owned by each Reporting Person is determined based on 117,267,482 Common Stock outstanding, as reported on the Issuer's 10-Q filed August 7, 2025.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Deep Track Biotechnology Master Fund, Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Kroin</signature>
        <title>David Kroin, Director</title>
        <date>08/25/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Deep Track Capital, LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Kroin</signature>
        <title>David Kroin, Managing Member of the General Partner of the Investment Adviser</title>
        <date>08/25/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>David Kroin</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Kroin</signature>
        <title>David Kroin</title>
        <date>08/25/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.I
<SEQUENCE>2
<FILENAME>ck0000000000-ex99_i.pdf
<DESCRIPTION>EX-99.I
<TEXT>
<PDF>
begin 644 ck0000000000-ex99_i.pdf
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MEIRS[HE#+@F]-("7I0'""V".*T*)H?Q-=G#K,;AQ[N8\CP@:G(L;Q XLG)/
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:(" @( H*<W1A<G1X<F5F"C$W,@HE)45/1@H!

end
</PDF>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
